A statement released earlier today by Stifel about Aerie Pharma (NASDAQ:AERI) bumps the target price to $55.00
- Updated: October 5, 2016
Stifel increased the target price of Aerie Pharma (NASDAQ:AERI) to $55.00 indicating a possible upside of 0.40%.
Just yesterday Aerie Pharma (NASDAQ:AERI) traded 0.36% higher at $39.26. Aerie Pharma’s 50-day moving average is $27.34 and its 200-day moving average is $19.13. With the last close up 105.91% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 31,909 shares of the stock were exchanged, down from an average trading volume of 1,088,500
See Chart Below
Aerie Pharma has 52 week low of $10.82 and a 52 week high of $41.72 and has a market cap of $0.
In addition to Stifel reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $45.71 with 3 firms rating the stock a strong buy, 3 firms rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.
More About Aerie Pharma (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.